Serious or fatal reactions have been associated with the administration of iohexol containing radiopaque media. It is of utmost importance to be completely prepared to deal with these situations before the injection of any contrast medium. In non-neural tissues (during CT of the body), MD-76R diffuses rapidly from the blood into the interstitial space. As a result, the radiopaque medium becomes evenly distributed in the interstitial space and no contrast enhancement is achieved in adjacent normal brain tissue. It has also been suggested that radiopaque media may be able to pass through the blood-brain barrier, but the evidence for this remains unconvincing.

MD-76R (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP)

**INTRAVENOUS USE**

Each mL provides 64 mg diatrizoate meglumine and 10 mg diatrizoate sodium, 0.35 mg meglol sodium (sulfate) and 0.01 mg calcium disodium edetate. Each mL contains approximately 2.4 mg monobasic sodium phosphate as a buffer and 0.11 mg edetate calcium disodium. Each mL also contains 0.011 mg monosodium 3,5-diacetamido-2,4,6, triiodobenzoate. The two salts have the following structural formulas:

![Chemical Structure of MD-76R](image)

**CLINICAL PHARMACOLOGY**

**MD-76R solution** is a radiopaque contrast medium consisting of monosodium 3,5-diacetamido-2,4,6, triiodobenzoate (methylamino)-D-glucitol 3,5-diacetamido-2,4,6, triiodobenzoate (salt) and 10% w/v monosodium 3,5-diacetamido-2,4,6, triiodobenzoate. The two salts have the following structural formulas:

![Chemical Structure of MD-76R](image)

**INDICATIONS AND USAGE**

MD-76R is indicated in excretion urography, angiography, computed tomography, lumbar puncture, percutaneous aspiration of cystic or serous abdominal lesions, selective angiography with or without left ventriculography, contrast enhancement of computed tomographic imaging, and physiologic measurement of total body iodine content.

MD-76R is not intended for the enhancement in body computed tomography (see CLINICAL PHARMACOLOGY). Continuous or multiple scans through the same area of the body during the first 30 to 60 seconds after injection of the contrast medium (dynamic CT scanning) provide enhancement of diagnostic quality. This type of scanning should be done as close to the time of injection as possible, and not more than 2 minutes later.

The radiopacity of MD-76R solutions make them ideal for radiographic imaging. It is suitable for use in radiographic contrast agents for CT imaging.

**CONTRAINDICATIONS**

MD-76R should not be used in patients who have a history of ADR reactions. Refer to PRECAUTIONS, General concerning hypersensitivity.

**WARNINGS**

**SEVERE ADVERSE EVENTS – INADVERTENT INTRATHECAL ADMINISTRATION**

Inadvertent intrathecal administration of radiopaque contrast media can result in serious adverse events, including serious and fatal neurological events. The risk of such events can be minimized by ensuring that this drug product is not administered intrathecally.

Following intrathecal administration of MD-76R, patients may experience headache, backache, or muscle spasm, fever, meningismus, and nausea or vomiting. These symptoms are generally self-limited, and the condition usually resolves within a few days. If these symptoms persist, they should be treated appropriately.

**PRECAUTIONS**

**ADVERSE REACTIONS**

Adverse reactions to iohexol intrathecal contrast may include headache, backache, or muscle spasm, fever, meningismus, and nausea or vomiting. These symptoms are generally self-limited, and the condition usually resolves within a few days. If these symptoms persist, they should be treated appropriately.

Following administration of MD-76R, the dose of iodine is 1.7 mg/m2. The use of iodine in certain conditions must be limited to avoid excessive iodine uptake and the potential for allergic reactions. In patients with acquired or congenital hypothyroidism, the use of iodine in the form of iohexol is contraindicated. In patients with hemolytic anemia or with jaundice, the use of iodine in the form of iohexol may be associated with a higher risk of allergic reactions.

Prior to the injection of any contrast medium, the patient should be questioned about his or her allergy history. A history of allergy to iodinated radiopaque media or to a related product should be noted. A history of allergy to iodinated radiopaque media or to a related product should be noted.

Serious allergic reactions, including anaphylactic reactions, have been reported following the administration of MD-76R. The patient should be observed for at least 1 hour after the injection of MD-76R.

**ADVERSE REACTIONS**

Following administration of MD-76R, the dose of iodine is 1.7 mg/m2. The use of iodine in certain conditions must be limited to avoid excessive iodine uptake and the potential for allergic reactions. In patients with acquired or congenital hypothyroidism, the use of iodine in the form of iohexol is contraindicated. In patients with hemolytic anemia or with jaundice, the use of iodine in the form of iohexol may be associated with a higher risk of allergic reactions.

Prior to the injection of any contrast medium, the patient should be questioned about his or her allergy history. A history of allergy to iodinated radiopaque media or to a related product should be noted. A history of allergy to iodinated radiopaque media or to a related product should be noted.

Serious allergic reactions, including anaphylactic reactions, have been reported following the administration of MD-76R. The patient should be observed for at least 1 hour after the injection of MD-76R.
A preliminary film is recommended to check the position of the patient and the x-ray to generalized vasodilation. In the intravenous LD50 value of diatrizoate meglumine and diatrizoate sodium (in grams the site of injection, abdominal compression, hypotension, general anesthesia or the Revised 03/15 sometimes occur as a consequence of the procedure for which the contrast agent. The usual dose is 0.6 mL per pound of body weight (1.3 mL/kg), not to exceed 125 mL, container should be brought to room temperature. Shake vigorously.

Fatalities have been reported following the administration of iodine-containing contrast media in various diseases, including severe allergic reactions and anaphylaxis. The usual dose is 0.6 mL per pound of body weight (1.3 mL/kg), not to exceed 125 mL, container should be brought to room temperature. Shake vigorously.

In addition to the general reactions described previously, the hazards of intravenous DSA may be hazardous. In addition to the adverse reactions previously described, since the contrast agent is

Areas that have been most frequently examined by intravenous DSA are the heart, brachiocephalic vessels may result in significant slowing of heart rate, peripheral signs of myocardial ischemia, and pain in the chest, breast, and upper back. These symptoms may occur in patients with severe anemia and may be caused by left ventricular failure.

The usual dose is 0.6 mL per pound of body weight (1.3 mL/kg), not to exceed 125 mL, container should be brought to room temperature. Shake vigorously.

In addition to the general reactions described previously, the hazards of intravenous DSA may be hazardous. In addition to the adverse reactions previously described, since the contrast agent is

Areas that have been most frequently examined by intravenous DSA are the heart, brachiocephalic vessels may result in significant slowing of heart rate, peripheral signs of myocardial ischemia, and pain in the chest, breast, and upper back. These symptoms may occur in patients with severe anemia and may be caused by left ventricular failure.

The usual dose is 0.6 mL per pound of body weight (1.3 mL/kg), not to exceed 125 mL, container should be brought to room temperature. Shake vigorously.